» Articles » PMID: 17073776

Biodiversity of CYP51 in Trypanosomes

Overview
Specialty Biochemistry
Date 2006 Nov 1
PMID 17073776
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Sterol 14alpha-demethylases (CYP51) are metabolic cytochromes P450, found in each biological kingdom. They catalyse a single three-step reaction included in all sterol biosynthetic pathways. Plant CYP51s have strict preference towards their physiological substrate O (obtusifoliol), which is C-4-monomethylated. Natural substrates of animal/fungal CYP51 (lanosterol, 24,25-dihydrolanosterol or 24-methylenelanosterol) are C-4-dimethylated. CYP51 from the pathogenic protozoa TB (Trypanosoma brucei) is the first example of O-specific sterol 14alpha-demethylase in non-photosynthetic organisms. Surprisingly, at 83% amino acid identity to the TB orthologue, CYP51 from TC (Trypanosoma cruzi) clearly prefers C-4-dimethylated sterols. Replacement of animal/fungi-like Ile(105) in the B' helix of TC CYP51 with phenylalanine, the residue found in this position in all plant and other trypanosome CYP51s, dramatically increases the ability of the enzyme to metabolize O, converting it into a more plant-like sterol 14alpha-demethylase. A more than 100-fold increase in binding and turnover is observed for the 24-desmethyl analogue of O [N (norlanosterol)], which is found in vivo in procyclic forms of TB and is a good TB CYP51 substrate in vitro. We believe that (i) N is a non-conventional CYP51 substrate, preferred in TB and perhaps other Trypanosomatidae and (ii) functional similarity of TC CYP51 to animal/fungal orthologues is a result of evolutionary convergence (including F105I mutation), leading to different pathways for sterol production in TC versus TB.

Citing Articles

Potent and selective inhibitors for M32 metallocarboxypeptidases identified from high-throughput screening of anti-kinetoplastid chemical boxes.

Salas-Sarduy E, Uran Landaburu L, Carmona A, Cazzulo J, Aguero F, Alvarez V PLoS Negl Trop Dis. 2019; 13(7):e0007560.

PMID: 31329594 PMC: 6675120. DOI: 10.1371/journal.pntd.0007560.


Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.

Riley J, Brand S, Voice M, Caballero I, Calvo D, Read K PLoS Negl Trop Dis. 2015; 9(9):e0004014.

PMID: 26394211 PMC: 4578769. DOI: 10.1371/journal.pntd.0004014.


Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group.

Xu K, Huang L, Xu Z, Wang Y, Bai G, Wu Q Drug Des Devel Ther. 2015; 9:1459-67.

PMID: 25792806 PMC: 4362653. DOI: 10.2147/DDDT.S74989.


Triazole derivatives with improved in vitro antifungal activity over azole drugs.

Yu S, Chai X, Wang Y, Cao Y, Zhang J, Wu Q Drug Des Devel Ther. 2014; 8:383-90.

PMID: 24748772 PMC: 3986111. DOI: 10.2147/DDDT.S58680.


Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.

Hargrove T, Wawrzak Z, Liu J, Waterman M, Nes W, Lepesheva G J Lipid Res. 2011; 53(2):311-20.

PMID: 22135275 PMC: 3269163. DOI: 10.1194/jlr.M021865.